News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
613,385 Results
Type
Article (47262)
Company Profile (242)
Press Release (565881)
Section
Business (176964)
Career Advice (2568)
Deals (32579)
Drug Delivery (111)
Drug Development (78795)
Employer Resources (161)
FDA (16215)
Job Trends (13608)
News (313296)
Policy (32428)
Tag
Academia (2408)
Alliances (44565)
Alzheimer's disease (1306)
Approvals (16124)
Artificial intelligence (138)
Bankruptcy (318)
Best Places to Work (10108)
Biotechnology (130)
Breast cancer (121)
Cancer (1094)
Cardiovascular disease (98)
Career advice (2138)
Cell therapy (247)
Clinical research (62658)
Collaboration (372)
Compensation (204)
COVID-19 (2613)
C-suite (95)
Data (1083)
Diabetes (158)
Diagnostics (5452)
Drug pricing (99)
Earnings (68753)
Employer resources (146)
Events (92421)
Executive appointments (297)
FDA (16757)
Funding (314)
Gene therapy (190)
GLP-1 (669)
Government (3957)
Healthcare (15897)
Infectious disease (2701)
Inflammatory bowel disease (110)
Interviews (470)
IPO (15164)
Job creations (3857)
Job search strategy (1802)
Layoffs (462)
Legal (7822)
Lung cancer (180)
Manufacturing (188)
Medical device (11415)
Medtech (11419)
Mergers & acquisitions (17499)
Metabolic disorders (461)
Neuroscience (1602)
NextGen Class of 2024 (5516)
Non-profit (3422)
Northern California (1415)
Obesity (270)
Opinion (229)
Patents (106)
People (51503)
Pharmaceutical (90)
Phase I (19249)
Phase II (27223)
Phase III (21239)
Pipeline (465)
Postmarket research (2597)
Preclinical (7853)
Radiopharmaceuticals (233)
Rare diseases (228)
Real estate (5390)
Regulatory (22021)
Research institute (2222)
Resumes & cover letters (425)
Southern California (1220)
Startups (3324)
United States (12658)
Vaccines (629)
Weight loss (221)
Date
Today (9)
Last 7 days (645)
Last 30 days (3501)
Last 365 days (34251)
2024 (31469)
2023 (37953)
2022 (48575)
2021 (52357)
2020 (49732)
2019 (40558)
2018 (30959)
2017 (31274)
2016 (30064)
2015 (33726)
2014 (27398)
2013 (23039)
2012 (24702)
2011 (25296)
2010 (23250)
Location
Africa (781)
Arizona (155)
Asia (38269)
Australia (6158)
California (3130)
Canada (1143)
China (230)
Colorado (143)
Connecticut (162)
Europe (86289)
Florida (441)
Georgia (101)
Illinois (302)
Indiana (172)
Maryland (559)
Massachusetts (2519)
Michigan (126)
Minnesota (238)
New Jersey (917)
New York (892)
North Carolina (701)
Northern California (1415)
Ohio (117)
Pennsylvania (776)
South America (1158)
Southern California (1220)
Texas (430)
Washington State (347)
613,385 Results for "ascendis pharma a s".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Ascendis Pharma Reports Third Quarter 2024 Financial Results
November 14, 2024
·
14 min read
Press Releases
Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs
September 20, 2024
·
5 min read
Press Releases
Ascendis Pharma A/S Announces Proposed Public Offering of ADSs
September 19, 2024
·
5 min read
Rare diseases
Ascendis’ Hypoparathyrodism Drug Secures FDA Approval Following Tough Regulatory Path
Ascendis Pharma’s palopegteriparatide was previously rejected by the regulator due to manufacturing problems, and the review period for its resubmitted application was extended by three months.
August 12, 2024
·
2 min read
·
Tristan Manalac
Business
Ascendis Pharma Reports First Quarter 2024 Financial Results
Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the first quarter ended March 31, 2024, and provided a business update.
May 2, 2024
·
12 min read
Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ PTH for Adults with Hypoparathyroidism
Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food and Drug Administration (FDA) notified the Company that information submitted in response to the FDA’s ongoing review of the New Drug Application (NDA) for TransCon PTH (palopegteriparatide) for adults with hypoparathyroidism constituted a major amendment to the NDA.
May 14, 2024
·
4 min read
Ascendis Pharma to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024, at 8:00 a.m. ET in Miami, Florida.
June 4, 2024
·
3 min read
Press Releases
Ascendis Pharma to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024
November 8, 2024
·
3 min read
Press Releases
Ascendis Pharma Receives Orphan Drug Exclusivity in the U.S. for YORVIPATH® (Palopegteriparatide) for the Treatment of Hypoparathyroidism in Adults
September 12, 2024
·
5 min read
Press Releases
Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases
November 5, 2024
·
6 min read
1 of 61,339
Next
